

STUDY PLANNING AND SITE OPTIMIZATION

Investigator/Site Training Platform

Exceptional Site Performance & Satisfaction Starts with an Exceptional Training Experience



ACCELERATED TIMELINES Gain 55 enrollment days through just in time training	REDUCE COSTS Cut training costs by over 60% compared to traditional delivery	IMPROVE QUALITY Reduce number of protocol deviations	INSPECTION READINESS Avoid the #1 finding of FDA Audits	SPONSOR OF CHOICE Reducing the burden of Site training by 50%
--	---	--	--	--

Highly Effective



Sites have a clear understanding of requirements and an improved ability to adhere to protocol and trial amendments

Automated Processes



A highly automated system that deploys training quickly, with complete, real time tracking.

Reduced Burden



Reduce the burden on Site staff of unnecessary and/or redundant training

Gain time for enrollment through just in time training




ACCELERATED TIMELINES

With an on-demand training rollout, protocol training is available as soon as the site is ready (contract complete, budget finalized, and regulatory ready).

Rapid Training Development & Deployment

Implement your training program **in 5 working days.**



Sponsors save over 60% or More in Costs with Training Available to Staff 24/7


REDUCE COSTS

The ROI for using Trifecta is easily realized based on face-to face investigator meeting costs, but the financial benefits go beyond that:

- Estimated Cost to Attend Investigator Meeting in 2020 - **\$2,400 per PERSON**
- Average Investigator Training Cost per site for Trifecta - **\$2,500 per SITE**

Reduction in Sponsor/CRO costs, for example:

- Reduction in overall Monitoring Costs due to less time on site for CRAs
- Reduction in Study Management time spent in audit preparation



REGENERON

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

- Type of human coronavirus, which also includes SARS, MERS
- Enveloped, positive-sense, single-stranded RNA virus with a ~30kb genome
- Encodes 4 structural proteins: spike (S), envelope (E), matrix/membrane (M), nucleocapsid (N)
- Putative antigenic determinant is the S glycoprotein studding viral envelope

TABLE OF CONTENTS

1. SARS-CoV-2 COVID-19 Background Anti-spike mAb MOA and Theoretical Risks
2. Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2
3. Coronavirus Disease 2019 (COVID-19)
4. SARS-CoV-2 infects human cells via ACE2 for efficient viral entry
5. Pharmacological properties of Regeneron
6. REGN10933 REGN10987: Theoretical risks
7. Thank You!

Opening Remarks - COVID-19 background, MoA and Safety Profile

Click here if you have a question about the material

Click Help if you are having technical difficulties

Click Close to exit the player

PRINT

Presentation 1 of 1. Total Running Time: 12:45


Training is available to site staff throughout the study

Improve Quality With Training That's More Accurate, Immediate, & Easy to Maintain



IMPROVE QUALITY

- Deliver “Just-in-Time” training across the study lifecycle
- Proprietary video-based training production process reduces asset creation time by 90%
- Updates & Amendments produced and available in 24 hours
- Immediate transformation of lessons learned into actionable guidance reduces data queries and data management/monitoring time
- Easy remediation of protocol deviations



INSPECTION READINESS

- ✓ Clinical Qualification Management System automates distribution, collection, and maintenance of all training documentation
- ✓ 100% security, auditability, & traceability
- ✓ Real-time compliance reporting provides total training process transparency

trifecta
investigator space

Certificate Summary

Judith Aberg
Regeneron | R10933-10987-COV-2066 (R10933-10987-COV-2066)

Certificate	Version	Status
GCP Training	1	100% (18-Jun-2020)

Topic Name	Completion Date	Expiration Date
ICH GCP Version: 2.0 / Language: English	18-Jun-2020	18-Jun-2023

Certificate	Version	Status
R10933-10987-COV-2066 (Original & Amendment 1) Protocol Training	1	100% (15-Jun-2020)

Topic Name	Completion Date	Expiration Date
Opening Remarks - COVID-19 background, MoA and Safety Profile Version: 1.0 / Language: English	15-Jun-2020	N/A
Study Design and Procedures, including Amendment 1 Version: 1.0 / Language: English	15-Jun-2020	N/A
Randomization Procedures Version: 1.1 / Language: English	15-Jun-2020	N/A

Certificate	Version	Status
R10933-10987-COV-2066 Amendment 2 Protocol Training	1	100% (26-Jun-2020)

Topic Name	Completion Date	Expiration Date
Amendment 2 Version: 1.0 / Language: English	26-Jun-2020	N/A

CERTIFICATE OF COMPLETION

provided to
Judith Aberg

R10933-10987-COV-2066 (Original & Amendment 1) Protocol Training

REGENERON

Name: Judith Aberg
Site #: 84001
Sponsor: Regeneron
Role: Principal Investigator
Protocol Number: R10933-10987-COV-2066
Certificate Date: 15-Jun-2020

Training Detail Record

Topic Name	Completion Date	Expiration Date
Opening Remarks - COVID-19 background, MoA and Safety Profile Version: 1.0 / Language: English	15-Jun-2020*	N/A
Study Design and Procedures, including Amendment 1 Version: 1.0 / Language: English	15-Jun-2020*	N/A
Randomization Procedures Version: 1.1 / Language: English	15-Jun-2020*	N/A

REGENERON

Name: Judith Aberg
Site #: 84001
Sponsor: Regeneron
Role: Principal Investigator
Protocol Number: R10933-10987-COV-2066
Certificate Date: 15-Jun-2020

Site Investigator Training Requirements

STUDY 1

Protocol W32
Mechanism of Action
SCORAD
GCP

STUDY 2

Protocol M91
GCP
SCORAD
eClinRO

STUDY 3

Protocol ZYY
Imaging Criteria
COX-2 Inhibition
GCP

STUDY 4

Protocol 45W
GCP
SCORAD
eCOA Tablet


Training Taken in Study 1 Automatically Credited for Any Additional Studies

In one year, more than **50% of Investigators** were exempt from redundant GCP training.

Exceptional Feedback on Trifecta Training in 2020

N=3,866 responses

“Based on your experience you would be likely to use a similar system in the future.”



“I found the online training system easy to use.”



“I found it easy to log in to the system using the instructions and information I received”



Level of Engagement



Level of Interaction



STRONGLY DISAGREE

STRONGLY AGREE